NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 10885.05 79.60 0.74%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Innate Pharma SA (EPA: IPH)

 

IPH Share Price

Open 9.40 Change Price %
High 9.45 1 Day -0.02 -0.21
Low 9.31 1 Week 0.00 0.00
Close 9.34 1 Month -0.80 -7.89
Volume 130474 1 Year -3.99 -29.93
52 Week High 15.83
52 Week Low 9.16
 
IPH Technical Analysis
5
As on 1st Nov 2017 IPH Share Price closed @ 9.34 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 11.59 & Strong Sell for SHORT-TERM with Stoploss of 10.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
VK 4.72 0.43%
ALALO 0.04 0.00%
CS 26.31 1.47%
TEC 67.40 0.40%
ACA 14.98 0.00%
ALAUP 0.20 -13.04%
 
EPA France Top Gainers Stocks
MLFCI 0.31 34.78%
AVT 0.19 26.67%
AVT 0.19 26.67%
AVT 0.19 26.67%
AVT 0.19 26.67%
ALFRE 1.81 25.69%
CFI 2.01 20.36%
CFI 2.01 20.36%
CFI 2.01 20.36%
CFI 2.01 20.36%
 
EPA France Top Losers Stocks
MLROU 6.37 -34.19%
MLLEA 0.61 -23.75%
ALAUP 0.20 -13.04%
OXI 0.08 -11.11%
OXI 0.08 -11.11%
MLFXO 3.79 -9.98%
TONN 1.20 -9.77%
ALCLS 26.88 -9.22%
RUSAL 10.00 -9.09%
ALEUP 0.20 -9.09%
 
 
IPH
Daily Charts
IPH
Intraday Charts
Whats New @
Bazaartrend
IPH
Free Analysis
 
IPH Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE9.47
RESISTANCE9.42
SUPPORT9.26
SUPPORT9.21
SUPPORT0.00
SUPPORT0.00
 
IPH Target for Month December
4th UP TARGET12.26
3rd UP TARGET11.33
2nd UP TARGET10.75
1st UP TARGET10.17
1st DOWN TARGET8.53
2nd DOWN TARGET7.95
3rd DOWN TARGET7.37
4th DOWN TARGET6.44
 
IPH Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
IPH Target for Year 2018
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
IPH Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.innate-pharma.com
 
IPH Address
IPH
117, Avenue de Luminy
Marseille, 13009
France
Phone: 33 4 30 30 30 30
Fax: 33 4 30 30 30 00
 
IPH Latest News
 
Your Comments and Response on Innate Pharma SA
 
IPH Business Profile
Innate Pharma S.A., a biopharmaceutical company, engages in the development of immunotherapy drug candidates for cancer and inflammatory diseases. The company primarily develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody (IgG4) blocking killer-cell immunoglobulin-like receptors (KIR) in Phase II trials for acute myeloid leukemia and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab respectively; and IPH2201/NN8765, an anti-NKG2A antibody in Phase I clinical trials for the treatment of inflammatory conditions and autoimmune diseases, and in rheumatoid arthritis. The company’s pre-clinical product candidates include IPH41, a cytotoxic mAb that targets KIR3DL2, an inhibitory receptor of NK cells; and IPH33, a blocking mAb targeting TLR3, an inducer of Type I IFN and pro-inflammatory cytokines. It has licensing agreements with Bristol-Myers Squibb for the development of IPH2102; and Novo Nordisk A/S for the development of IPH2201. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.
 
2005-2018 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service